期刊文献+

药物洗脱支架高度对药物浓度和壁面切应力分布影响的数值分析 被引量:5

Numerical analysis of effects from drug-eluting stent height on drug concentration and wall shear stress distribution
原文传递
导出
摘要 目的研究药物洗脱支架(drug-eluting stent,DES)突起高度对药物释放动力学和血流动力学的影响,为DES的优化设计提供依据。方法采用计算流体动力学(computational fluid dynamics,CFD)方法,对血流动力学和药物释放动力学进行耦合分析,考虑3种不同突起高度支架,研究血管壁组织中药物含量和壁面切应力的分布。结果支架突起高度的增加将有利于药物的沉积,但将增加低切应力区长度。比较而言,血管壁中药物含量随着突起高度增加的幅度远小于低切应力区长度的增加。结论综合考虑药物浓度和壁面切应力两种因素,建议适当降低支架的突起高度,以便更有效地降低再狭窄产生的几率。 Objective To investigate effects from the protrusion height of drug-eluting stent(DES) on kinetics of drug release and hemodynamics,so as to provide references for the optimization of DES design.Methods Based on computational fluid dynamics(CFD),coupling analysis on kinetics of drug release and hemodynamics was conducted by studying three stent models with different protrusion height to numerically investigate the distribution of drug concentration and wall shear stress.Results The increase in protrusion height of the stent was beneficial to the drug deposition;however,it could also increase the length in the low shear stress area.Comparatively,the increase percentage of drug concentration with the increasing protrusion height was remarkably less than that of the increasing length in low shear stress area.Conclusions By comprehensive consideration of both the drug concentration and wall shear stress,lower protrusion height is recommended for DES so as to effectively reduce the risk of restenosis.
出处 《医用生物力学》 EI CAS CSCD 北大核心 2012年第4期451-455,共5页 Journal of Medical Biomechanics
基金 国家自然科学基金资助项目(10872138)
关键词 药物洗脱支架 药物浓度 切应力 计算流体动力学 血流动力学 Drug-eluting stents Drug concentration Shear stress Computational fluid dynamics(CFD) Hemodynamics
  • 相关文献

参考文献4

二级参考文献71

  • 1鲁艳莉,宁喜斌.血栓形成机理及溶血栓药物的研究进展[J].食品研究与开发,2006,27(1):169-172. 被引量:22
  • 2高润霖.药物洗脱支架研究现状及进展[J].中国实用内科杂志,2006,26(8):1121-1123. 被引量:19
  • 3VIRMANI R,GUAGLIUM G,FARB A,et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent:should we be cautious? [J]. Circulation,2004,109(6) :701-705.
  • 4HONG MK, MINTZ GS,LEE CW, et al. Late stent malapposition after drug-eluting stent implantation : an intravascular ultrasound analysis with long-term follow-up [J].Circulation,2006,113 (3) :414- 419.
  • 5PFISTERER M, BRUNNER-LA ROCCA HP, BUSER PT,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents:an observational study of drug-eluting versus bare-metal stents [ J ]. J Am Coll Cardiol, 2006,48 (12):2584-2591.
  • 6FINN AV, JONER M, NAKAZAWA G, et al. Pathological correlates of late drug-eluting stent thrombosis : strut coverage as a marker of endothelialization [J]. Circulation, 2007,115 ( 18 ) : 2435-2441.
  • 7MARX SO,JAYARAMAN T,GO LO,et al. Rapamycin-FKBP in- hibits cell cycle regulators of proliferation in vascular smooth muscle cells [J]. Circ Res, 1995,76(3):412-417.
  • 8ROWINSKY EK,DONEHOWER C. Pactitaxel (taxol) [J]. N Engl J Med, 1995,332( 15 ) : 1004-1014.
  • 9TIAN W, KUHLMANN MT, PELISEK J, et al. Paclitaxel delivered to adventitia attenuates neointima formation without compromising re-endothelialization after angioplasty in a porcine restenosis model [ J ]. J Endovasc Ther. 2006 13 (5) : 616-629.
  • 10STONE GW,MOSES JW,ELLIS SG,et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents [J]. N Engl J Med, 2007,356(10) : 998-1008.

共引文献32

同被引文献123

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部